Eflapegrastim is a Recombinant Protein owned by Hanmi Pharmaceuticals, and is involved in 8 clinical trials, of which 6 were completed, and 2 are ongoing.

Eflapegrastim (HM-10460A, LAPS-GCSF,SPI-2012) is a long-acting G-CSF analog. G-CSF is hematopoietic growth factor acting on the neutrophilic lineage. It binds to the specific G-CSF receptors (G-CSFR) on cell surface and stimulates the differentiation, proliferation, and activation of the neutrophilic granulocytes. G-CSF regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation‚ differentiation and selected end-cell functional activation including enhanced phagocytic ability priming of the cellular metabolism associated with respiratory burst‚ antibody dependent killing.

The revenue for Eflapegrastim is expected to reach a total of $5.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Eflapegrastim NPV Report.

Eflapegrastim is originated and owned by Hanmi Pharmaceuticals. Spectrum Pharmaceuticals is the other company associated in development or marketing of Eflapegrastim.

Eflapegrastim Overview

Eflapegrastim (Rolontis) is recombinant human granulocyte colony stimulating factor analog derived from E.coli.  It is formulated as solution for subcutaneous route of administration. Rolontis is indicated for the treatment of severe neutropenia in patients receiving cytotoxic chemotherapy for solid cancer and malignant lymphoma.

Eflapegrastim (HM-10460A, LAPS-GCSF,SPI-2012) is under development for the treatment of chemotherapy induced neutropenia. The drug candidate is administered subcutaneously. It is a long-acting granulocyte colony-stimulating factor (G-CSF) analog. It is based on Lapscovery technology.

Spectrum Pharmaceuticals Overview

Spectrum Pharmaceuticals (Spectrum) is a biopharma company that acquires, develops, and commercializes novel drug candidates for treatment of cancer. The company’s pipeline products include ROLONTIS, for treatment of chemotherapy-induced neutropenia helps to reduce the frequency of multiplication of tumors. This product is in phase 3 trails.; Poziotinib, an irreversible tyrosine kinase inhibitor, for non-small cell lung cancer (NSCLC) tumors with various mutations. This product is in phase 2 trials and lead candidate for the organization. The company has R&D facilities in, Massachusetts and California, the US. The company operates in the US, Europe, Japan, and other countries. Spectrum is headquartered in Henderson, Nevada, the US.

The operating loss of the company was US$147.7 million in FY2021, compared to an operating loss of US$169.7 million in FY2020. The net loss of the company was US$158.6 million in FY2021, compared to a net loss of US$160.9 million in FY2020.

Quick View – Eflapegrastim

Report Segments
  • Innovator (NME)
Drug Name
  • Eflapegrastim
Administration Pathway
  • Subcutaneous
Therapeutic Areas
  • Toxicology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.